# A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

> **NCT05394831** · PHASE1,PHASE2 · RECRUITING · sponsor: **J Ints Bio** · enrollment: 150 (estimated)

## Conditions studied

- EGFR Mutant Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** JIN-A02

## Key facts

- **NCT ID:** NCT05394831
- **Lead sponsor:** J Ints Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394831, "A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05394831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*